Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056430 | 1.00 | SLC6A9 (0.46) | SLC6A9SLC6A3SLC6A2SLC6A4FLT1 | |
| SCHEMBL13618870 | 1.00 | SLC6A9 (0.46) | SLC6A9SLC6A3SLC6A2SLC6A4FLT1 | |
| SCHEMBL2056435 | 0.85 | NPC1 (0.40) | SLC6A9FLT1FLT4KDR | |
| SCHEMBL2054781 | 0.84 | AKT1 (0.46) | SLC6A9FLT1FLT4KDR | |
| SCHEMBL2056433 | 0.81 | SLC6A9 (0.51) | SLC6A9FLT1FLT4KDR | |
| SCHEMBL2054767 | 0.80 | MEN1 (0.46) | SLC6A9FLT1FLT4KDR | |
| SCHEMBL2056369 | 0.80 | SLC6A9 (0.75) | SLC6A9 | |
| SCHEMBL2056402 | 0.80 | SLC6A9 (0.75) | SLC6A9 | |
| SCHEMBL2056427 | 0.79 | SLC6A9 (0.51) | SLC6A9 | |
| SCHEMBL2056423 | 0.79 | SLC6A9 (0.51) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | SLC6A9 112/4885SLC6A3 16/4885SLC6A2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.